Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female 12 years of age or older with a minimum of 2 years of previous history of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.~* Signed informed consent form. For patients under the age of majority the parent or legal guardian should sign the consent form and the child will be required to sign a patient assent form.~* Documented positive allergic skin test to local pollen, performed within the past 12 months.~* A score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) with a minimum score of at least 2 for nasal congestion and a minimum score of at least 2 for one of the remaining 3 symptoms.~Exclusion Criteria:~* Females who are pregnant, lactating or likely to become pregnant during the study.~* History of asthma over the previous two years that required chronic therapy (with the exception of occasional acute or mild exercise induced asthma).~* Patients with some nasal conditions, or with clinically significant nasal deformity or any recent nasal surgery or trauma that has not completely healed.~* Upper respiratory tract infection or any untreated infections within the previous 30 days.~* Patient has started immunotherapy/changed the dose within 30 days of starting the study or has desensitization therapy to the seasonal allergen that is causing the allergic rhinitis within the previous 6 months.~* Patients with a history of tuberculosis, or with the presence of glaucoma, cataracts, ocular herpes simplex, conjunctivitis or other eye infection not related to the diagnosis of seasonal allergic rhinitis within 14 days of enrollment.~* The patient has had recent exposure (30 days) or was at risk of being exposed to chicken pox or measles.~* Any known hypersensitivity to mometasone, other steroids or any of the components of the study nasal spray.~* Planned travel outside of the local area for more than 2 consecutive days or 3 days in total.~* The patient has a history of alcohol or drug abuse.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test (Type: EXPERIMENTAL): Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
- Reference (Type: ACTIVE_COMPARATOR): Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo nasal spray administered once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).